



<https://doi.org/10.59298/ROJPHM/2025/538389>

Flavonoid-Rich Diets and Gut Microbiota Modulation in Obesity and Type 2 Diabetes: A Functional Food Perspective

Nassimbwa Kabanda D.

Faculty of Medicine Kampala International University Uganda

ABSTRACT

Obesity and Type 2 diabetes (T2D) are among the most prevalent metabolic disorders worldwide, contributing significantly to global healthcare burdens. Recent research highlights the profound impact of dietary interventions on the management and prevention of these conditions. Flavonoids, a group of polyphenolic compounds abundantly found in fruits, vegetables, and beverages such as tea and wine, have garnered attention for their potential in regulating metabolic health. Flavonoid-rich diets have been shown to modulate the gut microbiota, which plays a crucial role in metabolic processes and disease pathogenesis. This review explores the mechanisms by which flavonoids influence gut microbiota composition and function, focusing on their role in mitigating obesity and T2D. The relationship between gut microbiota and host metabolism is complex, involving the modulation of energy balance, inflammation, and insulin sensitivity. Flavonoid consumption can enrich beneficial microbial populations, such as those involved in short-chain fatty acid production, and inhibit the growth of harmful pathogens. Moreover, flavonoids exert direct effects on metabolic pathways, enhancing insulin sensitivity and reducing adiposity. We also discuss the clinical evidence supporting the use of flavonoid-rich foods as functional foods in the prevention and management of obesity and T2D. Finally, we highlight challenges and future directions for research, including the need for more well-designed clinical trials and personalized nutrition strategies.

Keywords: Flavonoids, Gut Microbiota, Obesity, Type 2 Diabetes, Functional Foods, Metabolic Health, Insulin Sensitivity, Short-Chain Fatty Acids; Diet Modulation.

INTRODUCTION

Obesity and type 2 diabetes (T2D) are chronic and interrelated metabolic disorders characterized by insulin resistance, impaired glucose metabolism, chronic low-grade inflammation, and an increased risk of cardiovascular diseases[1-4]. Over the past few decades, the global incidence of these conditions has surged dramatically, becoming a major public health concern[1, 5, 6]. The World Health Organization (WHO) estimates that more than 650 million adults worldwide are obese, while over 420 million individuals are living with diabetes, the majority of which are diagnosed with T2D. These statistics underscore the urgent need for effective strategies to prevent and manage these diseases, reduce healthcare burdens, and improve quality of life. Among the modifiable risk factors associated with obesity and T2D, dietary habits play a crucial role[7-10]. Consequently, nutritional interventions have emerged as essential components of therapeutic approaches. In recent years, interest has grown in the potential benefits of bioactive dietary compounds, particularly flavonoids, in combating metabolic disorders[11]. Flavonoids are naturally occurring polyphenolic compounds found abundantly in a wide array of plant-based foods, including fruits, vegetables, whole grains, legumes, nuts, seeds, and beverages such as tea, coffee, and red wine[12-14]. Flavonoids are subdivided into several classes, including flavonols, flavones, flavanones, isoflavones, flavanols (also known as catechins), and anthocyanins[15-17]. These compounds have been extensively studied for their potent antioxidant, anti-inflammatory, anti-obesity, and anti-diabetic properties. They exert their beneficial effects through various mechanisms, including the modulation of cellular signaling pathways, improvement of insulin sensitivity, reduction of oxidative stress, and

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

suppression of pro-inflammatory cytokines[18–20]. One of the most intriguing and rapidly emerging areas of flavonoid research is their interaction with the gut microbiota—a complex and dynamic community of trillions of microorganisms residing in the gastrointestinal tract. The gut microbiota is now recognized as a pivotal regulator of host metabolism. It influences numerous physiological processes, such as nutrient absorption, energy balance, immune response, and glucose and lipid metabolism. Dysbiosis, or an imbalance in gut microbiota composition, has been strongly linked to the pathogenesis of obesity, insulin resistance, and T2D[11, 21]. Flavonoids can modulate gut microbiota in several beneficial ways. First, they act as prebiotic-like compounds by selectively stimulating the growth of beneficial bacterial species such as *Lactobacillus* and *Bifidobacterium*, while inhibiting the proliferation of pathogenic microbes[22, 23]. Second, flavonoids and their metabolites serve as substrates for microbial fermentation, leading to the production of short-chain fatty acids (SCFAs) such as butyrate, acetate, and propionate[24–26]. These SCFAs have been shown to enhance gut barrier integrity, regulate appetite and satiety, modulate glucose homeostasis, and exert anti-inflammatory effects. Third, flavonoids can directly alter microbial gene expression and metabolic pathways, thus reshaping the overall functional capacity of the gut ecosystem[21, 27]. Moreover, the bidirectional relationship between flavonoids and gut microbiota suggests that while flavonoids influence microbial composition, the gut microbiota also metabolizes flavonoids into more bioactive and bioavailable forms[23, 28, 29]. This interplay enhances the therapeutic potential of flavonoids in managing metabolic disorders. For example, studies have shown that the intake of anthocyanin-rich foods such as berries improves insulin sensitivity and reduces body weight in obese individuals, effects that are partly mediated by changes in gut microbiota and SCFA production. The clinical implications of these findings are profound. Incorporating flavonoid-rich foods into the diet represents a natural, accessible, and cost-effective strategy to mitigate the risk of obesity and T2D. Functional foods and nutraceuticals formulated with concentrated flavonoid extracts are increasingly being investigated for their potential to serve as adjunctive therapies[30]. However, it is important to recognize that individual responses to flavonoid intake may vary depending on factors such as genetics, baseline gut microbiota composition, and overall dietary patterns. This review aims to comprehensively explore the role of flavonoid-rich diets in modulating the gut microbiota and their potential in the prevention and management of obesity and T2D. It will examine the molecular and microbial mechanisms by which flavonoids influence metabolic health, including improvements in insulin sensitivity, energy balance, and inflammatory status. Furthermore, the review will discuss the therapeutic prospects of integrating flavonoid-based interventions into clinical and dietary guidelines, particularly in the context of personalized nutrition and precision medicine. In sum, as the burden of metabolic diseases continues to rise, there is a pressing need to adopt holistic and integrative approaches that leverage the health-promoting properties of natural compounds like flavonoids. By modulating gut microbiota and enhancing metabolic resilience, flavonoid-rich diets hold promise as effective tools in the fight against obesity and type 2 diabetes.

Mechanisms of Flavonoid Action on Gut Microbiota

The gut microbiota is a complex and dynamic community consisting of trillions of microorganisms, including bacteria, viruses, fungi, and archaea[31–33]. These microbes play a fundamental role in maintaining human health by regulating critical physiological processes such as immune function, nutrient metabolism, and energy balance. A healthy and balanced gut microbiota contributes to the host's overall well-being, while disturbances in this microbial ecosystem referred to as dysbiosis can negatively impact metabolic homeostasis[34]. Dysbiosis has been increasingly linked to the development and progression of several metabolic disorders, particularly obesity and type 2 diabetes (T2D). Such imbalances in gut microbial composition may promote chronic inflammation, impair glucose regulation, and disrupt lipid metabolism, thereby contributing to disease onset[35]. Flavonoids, a diverse group of plant-derived polyphenolic compounds, have attracted considerable attention for their ability to modulate gut microbiota and influence metabolic health[13, 36]. One of the primary mechanisms by which flavonoids exert their beneficial effects is through their role as prebiotics. As prebiotics, flavonoids selectively stimulate the growth of beneficial bacterial strains such as *Bifidobacterium* and *Lactobacillus*, which are known for supporting gut barrier integrity, modulating immune responses, and producing anti-inflammatory metabolites. At the same time, flavonoids inhibit the proliferation of potentially pathogenic bacteria, including some members of the *Firmicutes* and *Proteobacteria* phyla, which are often associated with dysbiosis and metabolic dysfunction[37, 38]. A key metabolic byproduct of microbial fermentation of dietary fiber is the production of short-chain fatty acids (SCFAs), including acetate, propionate, and butyrate.[39–41] These SCFAs are essential for gut health and systemic metabolic regulation. They help maintain intestinal epithelial integrity, reduce local and systemic inflammation, and improve insulin sensitivity. Flavonoids, particularly subclasses such as flavonols and flavones, enhance the growth of SCFA-producing bacteria, thereby increasing SCFA levels in the gut.[39] This leads to improved metabolic outcomes such as reduced adiposity and enhanced glucose tolerance. Moreover, flavonoids can influence the gut-brain axis, a bidirectional communication system between the gastrointestinal tract and the central nervous system[42]. Through this pathway, flavonoids modulate the expression of hormones and neuropeptides involved in appetite regulation, such as leptin and ghrelin. By supporting satiety signaling and energy expenditure, flavonoids

contribute to appetite control and help prevent overeating, thus playing a potential role in the management and prevention of obesity.

Flavonoid-Rich Diets and Their Impact on Obesity

Obesity is characterized by excessive accumulation of body fat, which can lead to a range of metabolic disorders, including insulin resistance, chronic inflammation, and disrupted lipid metabolism [1, 2]. These conditions contribute to the development of type 2 diabetes, cardiovascular disease, and other obesity-related complications. In recent years, scientific research has increasingly focused on the role of dietary components in combating obesity [43]. Among these, flavonoids—naturally occurring polyphenolic compounds found in fruits, vegetables, teas, and other plant-based foods—have garnered significant attention for their potential anti-obesity effects. Flavonoids possess potent antioxidant and anti-inflammatory properties that help to counteract oxidative stress and chronic low-grade inflammation, both of which are closely linked to obesity and metabolic dysfunction [43]. Oxidative stress and inflammation promote adipocyte hypertrophy, or the enlargement of fat cells, leading to increased fat storage and impaired metabolic function. Flavonoids such as quercetin, anthocyanins, and catechins have been shown to inhibit adipocyte hypertrophy and reduce overall fat accumulation [44, 45]. These compounds also enhance lipolysis—the breakdown of stored fat—by activating key metabolic pathways, including AMP-activated protein kinase (AMPK), which plays a critical role in energy balance and cellular metabolism. In addition to promoting fat breakdown, flavonoids have been found to increase energy expenditure and improve fat oxidation, both of which are essential for effective weight management [16, 30]. By stimulating thermogenesis and enhancing mitochondrial function, flavonoids help the body burn more calories, even at rest. Furthermore, emerging evidence suggests that flavonoids may positively influence the composition and function of gut microbiota, which play a significant role in energy harvest and fat storage. By modulating the gut microbiome, flavonoids may reduce the capacity of intestinal microbes to extract calories from the diet, thereby lowering fat deposition [12, 22, 46]. Overall, incorporating flavonoid-rich foods into the diet—such as berries, apples, onions, green tea, and dark chocolate—can provide a natural and effective strategy for managing obesity and its associated metabolic disturbances. Continued research into the specific mechanisms and optimal dietary sources of flavonoids may offer promising avenues for the development of functional foods and targeted nutritional therapies aimed at preventing and treating obesity.

Flavonoids and Insulin Sensitivity in Type 2 Diabetes

Insulin resistance is a defining characteristic of type 2 diabetes (T2D), resulting in elevated blood glucose levels and disrupted insulin signaling. In individuals with T2D, insulin is either not produced in sufficient quantities or the body's cells do not respond effectively to it [15, 47, 48]. This resistance interferes with the proper regulation of glucose uptake and metabolism, ultimately contributing to chronic hyperglycemia and a range of metabolic complications. Recent research has highlighted the potential role of flavonoids, a group of naturally occurring polyphenolic compounds found in fruits, vegetables, and plant-based beverages, in enhancing insulin sensitivity and improving glycemic control [49]. Flavonoids exert their beneficial effects through multiple molecular pathways, with one of the most well-documented mechanisms being the activation of AMP-activated protein kinase (AMPK). AMPK is a key cellular energy sensor that plays a crucial role in maintaining metabolic balance. When activated, AMPK stimulates glucose uptake in peripheral tissues such as skeletal muscle and adipose tissue, while simultaneously suppressing glucose production in the liver. Flavonoids like quercetin, found in onions and apples, and epicatechin, found in green tea and cocoa, have demonstrated the ability to activate AMPK signaling [50]. This activation contributes to enhanced insulin sensitivity and improved glucose homeostasis. In addition to their role in energy metabolism, flavonoids possess strong anti-inflammatory properties. Chronic low-grade inflammation is a known contributor to insulin resistance and the progression of T2D [51]. Flavonoids help counter this by modulating the expression of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF- α) and interleukin-6 (IL-6), which are often elevated in individuals with metabolic disorders [51]. By reducing systemic inflammation, flavonoids support healthier insulin signaling pathways and prevent further metabolic dysfunction. Emerging clinical evidence supports the potential of flavonoid-rich foods and supplements to improve insulin sensitivity and glycemic control [30]. Studies have shown that the consumption of flavonoid-rich sources like citrus fruits, berries, cocoa, and tea can lead to improvements in glucose tolerance, reductions in fasting blood glucose, and lower HbA1c levels in patients with T2D [30, 36]. Despite these promising findings, more extensive and well-controlled clinical trials are needed to determine the optimal types, dosages, and duration of flavonoid interventions. Continued research may pave the way for integrating flavonoid-based strategies into the dietary management of T2D.

Clinical Evidence on Flavonoid-Rich Diets for Obesity and Type 2 Diabetes

Numerous studies have investigated the potential benefits of flavonoid-rich foods in individuals with obesity and T2D [52]. Clinical trials have shown that diets rich in flavonoids from fruits, vegetables, and beverages such as tea can lead to improvements in metabolic parameters, including reduced waist circumference, body mass index (BMI), and fasting blood glucose levels. For instance, a study involving individuals with T2D demonstrated that regular consumption of anthocyanins from berries improved insulin sensitivity and reduced postprandial blood glucose levels [52]. Similarly, quercetin supplementation has been shown to reduce body fat percentage

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

and improve lipid profiles in overweight individuals [53, 54]. While the evidence is promising, there is variability in the findings, which may be attributed to differences in study design, flavonoid composition, and dosages used. Thus, future research should focus on large-scale, well-designed clinical trials that examine the long-term effects of flavonoid-rich diets and the mechanisms underlying their benefits in obesity and T2D.

Challenges and Future Directions

Despite the promising evidence supporting the role of flavonoid-rich diets in metabolic health, several challenges remain. First, the bioavailability of flavonoids is relatively low, as they undergo extensive metabolism in the liver and gut before reaching target tissues. This limits the effectiveness of flavonoids in clinical applications and requires the development of strategies to enhance their bioavailability, such as the use of delivery systems or novel formulations. Second, the heterogeneity of the human gut microbiota and its response to dietary interventions presents another challenge. The impact of flavonoid-rich diets on gut microbiota composition may vary depending on individual microbiome profiles, necessitating personalized nutrition approaches. Future research should focus on elucidating the specific mechanisms through which flavonoids modulate gut microbiota and host metabolism, including the identification of key microbial species involved in the beneficial effects. Additionally, studies exploring the synergistic effects of flavonoids with other bioactive compounds, such as dietary fiber and prebiotics, are needed to better understand their potential as functional foods in managing obesity and T2D.

CONCLUSION

Flavonoid-rich diets represent a promising approach to managing obesity and T2D by modulating gut microbiota and improving metabolic health. Through their prebiotic effects, flavonoids promote beneficial bacterial populations, enhance SCFA production, and reduce inflammation, all of which contribute to improved insulin sensitivity and reduced adiposity. While clinical evidence supports their benefits, further research is required to optimize their use in clinical practice. Personalized nutrition strategies and advancements in delivery technologies will play a crucial role in harnessing the therapeutic potential of flavonoids in metabolic diseases.

REFERENCES

1. Achari, A.E., Jain, S.K.: Adiponectin, a Therapeutic Target for Obesity, Diabetes, and Endothelial Dysfunction. *Int J Mol Sci.* 18, 1321 (2017). <https://doi.org/10.3390/ijms18061321>
2. Annett, S., Moore, G., Robson, T.: Obesity and Cancer Metastasis: Molecular and Translational Perspectives. *Cancers.* 12, 3798 (2020). <https://doi.org/10.3390/cancers12123798>
3. Alum, E.U.: Optimizing patient education for sustainable self-management in type 2 diabetes. *Discov Public Health.* 22, 44 (2025). <https://doi.org/10.1186/s12982-025-00445-5>
4. Uti, D.E., Atangwho, I.J., Omang, W.A., Alum, E.U., Obeten, U.N., Udeozor, P.A., Agada, S.A., Bawa, I., Ogbu, C.O.: Cytokines as key players in obesity low grade inflammation and related complications. *Obesity Medicine.* 54, 100585 (2025). <https://doi.org/10.1016/j.obmed.2025.100585>
5. Anguita-Ruiz, A., Bustos-Aibar, M., Plaza-Díaz, J., Mendez-Gutierrez, A., Alcalá-Fdez, J., Aguilera, C.M., Ruiz-Ojeda, F.J.: Omics Approaches in Adipose Tissue and Skeletal Muscle Addressing the Role of Extracellular Matrix in Obesity and Metabolic Dysfunction. *International Journal of Molecular Sciences.* 22, 2756 (2021). <https://doi.org/10.3390/ijms22052756>
6. Amor, A.J., Gómez-Guerrero, C., Ortega, E., Sala-Vila, A., Lázaro, I.: Ellagic Acid as a Tool to Limit the Diabetes Burden: Updated Evidence. *Antioxidants (Basel).* 9, 1226 (2020). <https://doi.org/10.3390/antiox9121226>
7. Alum, E., P.C., U., Obeagu, E., Extension, K.P.: Beyond Pregnancy: Understanding the Long-Term Implications of Gestational Diabetes Mellitus. *INOSR Scientific Research.* 11, 63–71 (2024). <https://doi.org/10.59298/INOSRSR/2024/1.1.16371>
8. Ahmad, K., Shaikh, S., Lim, J.H., Ahmad, S.S., Chun, H.J., Lee, E.J., Choi, I.: Therapeutic application of natural compounds for skeletal muscle-associated metabolic disorders: A review on diabetes perspective. *Biomedicine & Pharmacotherapy.* 168, 115642 (2023). <https://doi.org/10.1016/j.biopha.2023.115642>
9. Donate-Correa, J., Martín-Núñez, E., Mora-Fernández, C., González-Luis, A., Martín-Olivera, A., Navarro-González, J.F.: Associations between Inflammation, Hemoglobin Levels, and coronary artery disease in Non-Albuminuric Subjects with and without Type 2 Diabetes Mellitus. *International Journal of Molecular Sciences.* 24, 14131 (2023). <https://doi.org/10.3390/ijms241814131>
10. Alum, E., P.C., U., Obeagu, E., Aja, P., Ugwu, C., Okon, M.: Nutritional Care In Diabetes Mellitus: A Comprehensive Guide. 11, 16–15 (2023). <https://doi.org/10.58538/IJIAR/2057>
11. Samtiya, M., Aluko, R.E., Dhewa, T., Moreno-Rojas, J.M.: Potential Health Benefits of Plant Food-Derived Bioactive Components: An Overview. *Foods.* 10, 839 (2021). <https://doi.org/10.3390/foods10040839>
12. Bouyahya, A., Balahbib, A., Khalid, A., Makeen, H.A., Alhazmi, H.A., Albratty, M., Hermansyah, A., Ming, L.C., Goh, K.W., El Omari, N.: Clinical applications and mechanism insights of natural flavonoids against type 2 diabetes mellitus. *Heliyon.* 10, e29718 (2024). <https://doi.org/10.1016/j.heliyon.2024.e29718>

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

13. Intharuksa, A., Kuljarusnont, S., Sasaki, Y., Tungmunnithum, D.: Flavonoids and Other Polyphenols: Bioactive Molecules from Traditional Medicine Recipes/Medicinal Plants and Their Potential for Phytopharmaceutical and Medical Application. *Molecules*. 29, 5760 (2024). <https://doi.org/10.3390/molecules29235760>
14. Uti, D.E., Atangwho, I.J., Alum, E.U., Egba, S.I., Ugwu, O.P.-C., Ikechukwu, G.C.: Natural Antidiabetic Agents: Current Evidence and Development Pathways from Medicinal Plants to Clinical use. *Natural Product Communications*. 20, 1934578X251323393 (2025). <https://doi.org/10.1177/1934578X251323393>
15. Zhou, M., Konigsberg, W.H., Hao, C., Pan, Y., Sun, J., Wang, X.: Bioactivity and mechanisms of flavonoids in decreasing insulin resistance. *J Enzyme Inhib Med Chem*. 38, 2199168. <https://doi.org/10.1080/14756366.2023.2199168>
16. Ioannou, I., Chekir, L., Ghoul, M.: Effect of Heat Treatment and Light Exposure on the Antioxidant Activity of Flavonoids. *Processes*. 8, 1078 (2020). <https://doi.org/10.3390/pr8091078>
17. Alum, E.U., Ugwu, O.P.C., Department of Publication and Extension Kampala International University Uganda: Beyond Nutrients: Exploring the Potential of Phytochemicals for Human Health. *IAA JAS*. 10, 1–7 (2023). <https://doi.org/10.59298/IAAJAS/2023/4.1.3211>
18. Borrero, L.J.H., El-Deiry, W.S.: Tumor Suppressor p53: Biology, Signaling Pathways, and Therapeutic Targeting. *Biochim Biophys Acta Rev Cancer*. 1876, 188556 (2021). <https://doi.org/10.1016/j.bbcan.2021.188556>
19. Mustafa, M., Ahmad, R., Tantry, I.Q., Ahmad, W., Siddiqui, S., Alam, M., Abbas, K., Moinuddin, Hassan, M.I., Habib, S., Islam, S.: Apoptosis: A Comprehensive Overview of Signaling Pathways, Morphological Changes, and Physiological Significance and Therapeutic Implications. *Cells*. 13, 1838 (2024). <https://doi.org/10.3390/cells13221838>
20. Sayem, A.S.M., Arya, A., Karimian, H., Krishnasamy, N., Ashok Hasamnis, A., Hossain, C.F.: Action of Phytochemicals on Insulin Signaling Pathways Accelerating Glucose Transporter (GLUT4) Protein Translocation. *Molecules*. 23, 258 (2018). <https://doi.org/10.3390/molecules23020258>
21. Fakharian, F., Thirugnanam, S., Welsh, D.A., Kim, W.-K., Rappaport, J., Bittinger, K., Rout, N.: The Role of Gut Dysbiosis in the Loss of Intestinal Immune Cell Functions and Viral Pathogenesis. *Microorganisms*. 11, 1849 (2023). <https://doi.org/10.3390/microorganisms11071849>
22. Xiong, H.-H., Lin, S.-Y., Chen, L.-L., Ouyang, K.-H., Wang, W.-J.: The Interaction between Flavonoids and Intestinal Microbes: A Review. *Foods*. 12, 320 (2023). <https://doi.org/10.3390/foods12020320>
23. Mansour, H., Slika, H., Nasser, S.A., Pintus, G., Khachab, M., Sahebkar, A., Eid, A.H.: Flavonoids, gut microbiota and cardiovascular disease: Dynamics and interplay. *Pharmacological Research*. 209, 107452 (2024). <https://doi.org/10.1016/j.phrs.2024.107452>
24. Facchin, S., Bertin, L., Bonazzi, E., Lorenzon, G., De Barba, C., Barberio, B., Zingone, F., Maniero, D., Scarpa, M., Ruffolo, C., Angriman, I., Savarino, E.V.: Short-Chain Fatty Acids and Human Health: From Metabolic Pathways to Current Therapeutic Implications. *Life (Basel)*. 14, 559 (2024). <https://doi.org/10.3390/life14050559>
25. Liu, M., Lu, Y., Xue, G., Han, L., Jia, H., Wang, Z., Zhang, J., Liu, P., Yang, C., Zhou, Y.: Role of short-chain fatty acids in host physiology. *Animal Models and Experimental Medicine*. 7, 641–652 (2024). <https://doi.org/10.1002/ame2.12464>
26. Zhang, D., Jian, Y.-P., Zhang, Y.-N., Li, Y., Gu, L.-T., Sun, H.-H., Liu, M.-D., Zhou, H.-L., Wang, Y.-S., Xu, Z.-X.: Short-chain fatty acids in diseases. *Cell Communication and Signaling*. 21, 212 (2023). <https://doi.org/10.1186/s12964-023-01219-9>
27. Albillos, A., de Gottardi, A., Rescigno, M.: The gut-liver axis in liver disease: Pathophysiological basis for therapy. *J Hepatol*. 72, 558–577 (2020). <https://doi.org/10.1016/j.jhep.2019.10.003>
28. Cronin, P., Joyce, S.A., O'Toole, P.W., O'Connor, E.M.: Dietary Fibre Modulates the Gut Microbiota. *Nutrients*. 13, 1655 (2021). <https://doi.org/10.3390/nu13051655>
29. Bié, J., Sepodes, B., Fernandes, P.C.B., Ribeiro, M.H.L.: Polyphenols in Health and Disease: Gut Microbiota, Bioaccessibility, and Bioavailability. *Compounds*. 3, 40–72 (2023). <https://doi.org/10.3390/compounds3010005>
30. Thompson, A.S., Jennings, A., Bondonno, N.P., Tresserra-Rimbau, A., Parmenter, B.H., Hill, C., Perez-Cornago, A., Kühn, T., Cassidy, A.: Higher habitual intakes of flavonoids and flavonoid-rich foods are associated with a lower incidence of type 2 diabetes in the UK Biobank cohort. *Nutr Diabetes*. 14, 32 (2024). <https://doi.org/10.1038/s41387-024-00288-0>
31. Chen, J., Chen, B., Lin, B., Huang, Y., Li, J., Li, J., Chen, Z., Wang, P., Ran, B., Yang, J., Huang, H., Liu, L., Wei, Q., Ai, J., Cao, D.: The role of gut microbiota in prostate inflammation and benign prostatic hyperplasia and its therapeutic implications. *Heliyon*. 10, e38302 (2024). <https://doi.org/10.1016/j.heliyon.2024.e38302>

32. Liu, J., Tan, Y., Cheng, H., Zhang, D., Feng, W., Peng, C.: Functions of Gut Microbiota Metabolites, Current Status and Future Perspectives. *Aging Dis.* 13, 1106–1126 (2022). <https://doi.org/10.14336/AD.2022.0104>
33. Ugwu, O.P.-C., Alum, E.U., Okon, M.B., Obeagu, E.I.: Mechanisms of microbiota modulation: Implications for health, disease, and therapeutic interventions. *Medicine.* 103, e38088 (2024). <https://doi.org/10.1097/MD.00000000000038088>
34. DeGruttola, A.K., Low, D., Mizoguchi, A., Mizoguchi, E.: Current understanding of dysbiosis in disease in human and animal models. *Inflamm Bowel Dis.* 22, 1137–1150 (2016). <https://doi.org/10.1097/MIB.0000000000000750>
35. Petersen, C., Round, J.L.: Defining dysbiosis and its influence on host immunity and disease. *Cellular Microbiology.* 16, 1024 (2014). <https://doi.org/10.1111/cmi.12308>
36. Mahboob, A., Samuel, S.M., Mohamed, A., Wani, M.Y., Ghorbel, S., Miled, N., Büsselberg, D., Chaari, A.: Role of flavonoids in controlling obesity: molecular targets and mechanisms. *Front. Nutr.* 10, (2023). <https://doi.org/10.3389/fnut.2023.1177897>
37. Plamada, D., Vodnar, D.C.: Polyphenols—Gut Microbiota Interrelationship: A Transition to a New Generation of Prebiotics. *Nutrients.* 14, 137 (2021). <https://doi.org/10.3390/nu14010137>
38. Kumari, T., Bag, K.K., Das, A.B., Deka, S.C.: Synergistic role of prebiotics and probiotics in gut microbiome health: Mechanisms and clinical applications. *Food Bioengineering.* 3, 407–424 (2024). <https://doi.org/10.1002/fbe2.12107>
39. Armet, A.M., Deehan, E.C., Thöne, J.V., Hewko, S.J., Walter, J.: The Effect of Isolated and Synthetic Dietary Fibers on Markers of Metabolic Diseases in Human Intervention Studies: A Systematic Review. *Advances in Nutrition.* 11, 420–438 (2020). <https://doi.org/10.1093/advances/nmz074>
40. Ciudad-Mulero, M., Fernández-Ruiz, V., Matallana-González, M.C., Morales, P.: Chapter Two - Dietary fiber sources and human benefits: The case study of cereal and pseudocereals. In: Ferreira, I.C.F.R. and Barros, L. (eds.) *Advances in Food and Nutrition Research.* pp. 83–134. Academic Press (2019)
41. Liu, J., An, Y., Yang, N., Xu, Y., Wang, G.: Longitudinal associations of dietary fiber and its source with 48-week weight loss maintenance, cardiometabolic risk factors and glycemic status under metformin or acarbose treatment: a secondary analysis of the March randomized trial. *Nutr. Diabetes.* 14, 1–9 (2024). <https://doi.org/10.1038/s41387-024-00340-z>
42. Wang, H., Zhao, T., Liu, Z., Danzengquzhen, Cisangzhuoma, Ma, J., Li, X., Huang, X., Li, B.: The neuromodulatory effects of flavonoids and gut Microbiota through the gut-brain axis. *Front Cell Infect Microbiol.* 13, 1197646 (2023). <https://doi.org/10.3389/fcimb.2023.1197646>
43. Powell-Wiley, T.M., Poirier, C.P., Burke, V.C.L.E., Després, J.-P., Gordon-Larsen, P., Lavie, C.J., Lear, S.A., Ndumele, C.E., Neeland, I.J., Sanders, P., St-Onge, M.-P.: Obesity and Cardiovascular Disease. *Circulation.* 143, e984–e1010 (2021). <https://doi.org/10.1161/CIR.0000000000000973>
44. Al-Kafaji, G., Golbahar, J.: High Glucose-Induced Oxidative Stress Increases the Copy Number of Mitochondrial DNA in Human Mesangial Cells. *BioMed Research International.* 2013, 754946 (2013). <https://doi.org/10.1155/2013/754946>
45. Udeozor, P.A., Ibiam, U.A., Uti, D.E., Umoru, G.U., Onwe, E.N., Mbonu, F.O., Omang, W.A., Ijoganu, S.I., Anaga, C.O., Mbah, J.O., Nwadam, S.K.: Antioxidant and Anti-Anemic Effects of Ethanol Leaf Extracts of *Mucuna poggiei* and *Telfairia occidentalis* in Phenyl-Hydrazine-Induced Anemia in Wistar Albino Rats. *Ibnosina Journal of Medicine and Biomedical Sciences.* 14, 116–126 (2022). <https://doi.org/10.1055/s-0042-1756684>
46. Liga, S., Paul, C., Péter, F.: Flavonoids: Overview of Biosynthesis, Biological Activity, and Current Extraction Techniques. *Plants.* 12, 2732 (2023). <https://doi.org/10.3390/plants12142732>
47. Cao, C., Su, M.: Effects of berberine on glucose-lipid metabolism, inflammatory factors and insulin resistance in patients with metabolic syndrome. *Exp Ther Med.* 17, 3009–3014 (2019). <https://doi.org/10.3892/etm.2019.7295>
48. MacDonald-Ramos, K., Monroy, A., Bobadilla-Bravo, M., Cerbón, M.: Silymarin Reduced Insulin Resistance in Non-Diabetic Women with Obesity. *Int J Mol Sci.* 25, 2050 (2024). <https://doi.org/10.3390/ijms25042050>
49. Alum, E.U., Umoru, G.U., Uti, D.E., Aja, P.M., Ugwu, O.P., Orji, O.U., Nwali, B.U., Ezeani, N.N., Edwin, N., Orinya, F.O.: Hepato-Protective Effect Of Ethanol Leaf Extract Of *Datura Stramonium* In Alloxan-Induced Diabetic Albino Rats. *Journal of Chemical Society of Nigeria.* 47, (2022). <https://doi.org/10.46602/jcsn.v47i5.819>
50. Guerrero-Becerra, L., Morimoto, S., Arrellano-Ordoñez, E., Morales-Miranda, A., Guevara-Gonzalez, R.G., Feregrino-Pérez, A.A., Lomas-Soria, C.: Polyphenolic Compounds in Fabaceous Plants with Antidiabetic Potential. *Pharmaceuticals.* 18, 69 (2025). <https://doi.org/10.3390/ph18010069>

51. Sinuhaji, T.R.F., Ramadhani, S., Setiawan, V.K., Baroroh, U.: Targeting diabetes with flavonoids from Indonesian medicinal plants: a review on mechanisms and drug discovery. *Naunyn-Schmiedeberg's Arch Pharmacol.* (2025). <https://doi.org/10.1007/s00210-025-04139-2>
52. Alkhalidy, H., Wang, Y., Liu, D.: Dietary Flavonoids in the Prevention of T2D: An Overview. *Nutrients.* 10, 438 (2018). <https://doi.org/10.3390/nu10040438>
53. Frent, O.-D., Stefan, L., Morgovan, C.M., Duteanu, N., Dejeu, I.L., Marian, E., Vicaș, L., Manole, F.: A Systematic Review: Quercetin—Secondary Metabolite of the Flavonol Class, with Multiple Health Benefits and Low Bioavailability. *Int J Mol Sci.* 25, 12091 (2024). <https://doi.org/10.3390/ijms252212091>
54. Khan, H., Ullah, H., Aschner, M., Cheang, W.S., Akkol, E.K.: Neuroprotective Effects of Quercetin in Alzheimer's Disease. *Biomolecules.* 10, 59 (2020). <https://doi.org/10.3390/biom10010059>

CITE AS: Nassimbwa Kabanda D. (2025) Flavonoid-Rich Diets and Gut Microbiota Modulation in Obesity and Type 2 Diabetes: A Functional Food Perspective. *Research Output Journal of Public Health and Medicine* 5(3):83-89. <https://doi.org/10.59298/ROJPHM/2025/538389>